In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples in years are very attractive for many investors. Here are the top…
courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage…
After retreating from many leading biotech and emerging pharmaceutical stocks in the previous two periods, short sellers returned in early March, especially in Celgene, Medivation and Pharmacyclics.
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a…
Biotech and emerging pharmaceutical stocks continue to be hot, but short sellers shied away from many of them in late February. Those bucking that trend include BioMarin Pharmaceutical and Medivation.
After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical stocks in early February. The largest upswings happened to BioMarin Pharmaceutical and…
24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers shied away from these stocks in late January.
Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences report earnings on Thursday.
Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across the board.…
Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we focused on the quality large cap names and the stocks with the…
Celgene has issued its preliminary numbers ahead of its presentations at the 32nd Annual J.P. Morgan Healthcare Conference. There is some confusion over near-term guidance, which hit the stock a bit.
Jon C. Ogg These are the top analyst downgrades and cautious research notes from Wall Street for Monday, January 6.
The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.
ThinkstockCredit Suisse is out and pounding the table that biotechnology cannot be ignored in 2014. Biotech has been the top-performing sector for the past three years, with year-to-date performance up 73%. Given…
Jon OggStocks are looking for direction after the first week of a sell-off on the heels of eight weeks of a rally. At the same time, investors are getting ready for year-end…
